ALKEUS PHARMACEUTICALS, INC.
ALK-001, an oral chemically-modified vitamin A therapeutic to prevent age-related macular degeneration
- Sector
- Biotech
- Total capital
- $4.2M
- Federal grants
- $4.2M
- 3 awards · 2016–2017
- Rank in peer group#221 of 514
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 7 pending
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · A Phase 2a clinical trial of ALK-001 in geographic atrophy$1M
- Federal grantHealth and Human S · Phase II · A Phase a clinical trial of ALK in geographic atrophy$2.1M
- Federal grantHealth and Human S · Phase II · A Phase 2a clinical trial of ALK-001 in geographic atrophy$1.1M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grants#221 · top 43%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 0 granted of 7- PendingDosage Regimens For Treating Geographic Atrophy And Neovascular Age-related Macular DegenerationUSPTOApplication PCTUS2025044210
- PendingDosage Regimens For Treating Stargardt DiseaseUSPTOApplication PCTUS2024062409
- PendingTreatment For Asymptomatic Stargardt Disease PatientsUSPTOApplication PCTUS2024062408
Show all 7 patent records
- Dosage Regimens For Treating Geographic Atrophy And Neovascular Age-related Macular DegenerationApplication PCTUS2025044210Pending
- Dosage Regimens For Treating Stargardt DiseaseApplication PCTUS2024062409Pending
- Treatment For Asymptomatic Stargardt Disease PatientsApplication PCTUS2024062408Pending
- Dosage Regimens For Treating Geographic Atrophy And Neovascular Age-related Macular DegenerationApplication 63689532Pending
- Dosage Regimens For Treating Stargardt DiseaseApplication 63617012Pending
- Treatment For Asymptomatic Stargardt Disease PatientsApplication 63617005Pending
- Treatment For Asymptomatic Stargardt Disease PatientsApplication PCTUS2024010064Pending
Related companies, and why
- EXBAQ LLCSimilar federal contract value in Biotech · null in contracts
- General Payment Systems, Inc.Similar federal contract value in Biotech · null in contracts
- Carogen CorporationSimilar federal contract value in Biotech · null in contracts
- IMMUNIC, INC.Similar federal contract value in Biotech · null in contracts
- IRONWOOD PHARMACEUTICALS INCSimilar federal contract value in Biotech · null in contracts
- Lycia TherapeuticsSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .